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include disodium pamidronate, alendronic acid, ibandronate sodium, risedronate sodium and zoledronic acid. 7 These compounds decrease osteoclast function and hence modulate bone resorption; the process occurs through a number of mechanisms, particularly inhibition of the enzyme farnesyl diphosphate synthase. 7 In CRPS, aminobisphosphonates seem to be most effective in high doses and in the current trial, 2 100 mg doses of neridronate were given intravenously four times over 10 days, estimated to be equivalent to pamidronate at 90 mg given four times over 4-10 days.
A ≥50% reduction of the pain VAS score was seen in 73% of patients in the neridronate group versus 32% in the placebo group, at 40 days (a 40.7% treatment difference; 95% CI 20.8-60.5%, P = 0.0003). 2 Reduction in pain was associated with decreased allodynia, hyperalgesia and oedema, and improvements in quality of life indices correlated with these painrelated clinical outcomes. Subsequent treatment of patients from the placebo group after the 40-day mark with the active medication produced similar outcomes to those in the patients initially treated with neridronate, such that in the total group, no patient had clinical features of CRPS at 1 year. The study entry criteria note that all these patients initially had CRPS for less than 4 months and all showed abnormal changes on bone scintigraphy scans; these features identify a sub-group of patients with CRPS who are likely to have active bone-related pain mechanisms. 2 Given these promising results, are there any downsides to using bisphosphonates as early as practical in CRPS? Almost a third of patients treated with neridronate developed polyarthralgia and a fifth developed fever at the time of infusion, with much lower frequencies in the placebo group. 2 These findings are to be expected with high-dose parenteral bisphosphonate therapy and require co-administration of paracetamol during the course of the infusions. Routine assessments to check for renal impairment or low levels of vitamin D or calcium prior to infusion will minimize other adverse effects of bisphosphonates, such as hypocalcaemia. The risk of osteonecrosis of the jaw has not been evaluated in this setting.
How bisphosphonates influence the mechanisms that drive CRPS is unknown. Substantial changes in bone physiology in CRPS are reflected in various imaging abnormalities early in the clinical course.
These features include signs of bone marrow oedema on MRI scans, osteopenia and/or osteoporosis on plain radiographs and change in blood flow on technetium perfusion bone scans. These changes probably relate to the effects on bone of the various inflammatory mediators that are upregulated in CRPS. Bisphosphonates might modulate these effects, particularly the release of protons from activated osteoclasts, thus reducing the acidic sensitization of bone nociceptors. 7 Perhaps in patients with bisphosphonate-responsive CRPS, these peripheral bone-related mechanisms provide key counteracting input to the amplified nociceptive feedback loops described above, and the abnormal pain response seen in CRPS is subsequently downregulated. Notably, bisphosphonates also have effects on cells other than osteoclasts, such as macrophages and microglia, including those that produce the pro-nociceptive β-NGF. This microgliamediated mechanism may account for the potent antinociceptive effects of bisphosphonates seen in various animal models of non-bone pain, emphasizing the additional central actions of bisphosphonates on pain. 7 The effects of bisphosphonates in CRPS raise new questions about the mechanisms of CRPS and about the pleiotropic qualities of bisphosphonates. In adults, early use of high-dose nitrogen-based bisphosphonates now rates high on the evidencebased list of appropriate treatments for this enigmatic condition. Allopurinol is the most commonly used medication for the treatment of hyperuricaemia in patients with gout. Allopurinol hypersensitivity syndrome (AHS) is a rare but important complication of allo purinol therapy, given that the associated mortality rate can be as high as 20-30%. Although the precise incidence of AHS is unknown, among those treated with allopurinol it has been estimated at between 0.1-0.4%. 1 AHS is a type of severe cutaneous adverse reaction (SCAR). SCARs manifest as druginduced hypersensitivity syndromes (such as AHS), Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Indeed, allopurinol has also been shown to be one of most frequent causes of SJS and TEN.
2 Allopurinol-associated SCARs can present with skin rash, fever, hepatitis and acute renal failure, and patients with these conditions can also have leukocytosis and/or eosinophilia. 3 Recently, Hershfield et al. 4 presented clinical recommendations for the management of gout that highlighted the role of the HLAB*5801 allele in the occurrence of allopurinol-induced SCARs, including AHS. Recognition of the association between HLAB*5801 and allopurinol-induced SCARs could advance gout pharmaco genomics and improve prediction of allopurinol hyper sensitivity, thus increasing the safety profile of this effective therapeutic.
The systematic literature review conducted by Hershfield et al. 4 identified pharmaco genetic data demonstrating association of the HLAB*5801 allele with allopurinol-induced SCARs, updating a meta-analysis conducted previously by Zineh and colleagues. 5 Hershfield et al. 4 summarized studies that reported strong positive associations of HLAB*5801 with allopurinol-associated SCARs in various populations, including one study each in Han Chinese, Thai, Japanese, Korean and European populations. 4 Each study included in the analysis used a population control group and two studies also included an allopurinol-tolerant control group (Han Chinese and Korean indivi duals). 4 In addition, the previously mentioned metaanalysis 5 provided a pooled odds ratio for allopurinol-induced SCARs in HLAB*5801 carriers of 90 (95% CI 36-231), compared with all controls (healthy controls and allopurinol-tolerant controls). On the basis of the pharmaco genetic data analysed, Hershfield and co-workers 4 provided recom mendations for the clinical use of allo purinol in indivi duals who have un dergone HLAB*5801 genotyping.
Current guidelines for the treatment of gout recommend starting allopurinol at 100 mg per day in patients with normal renal function, escalating to 800 mg daily (or more) as needed to control hyper uricaemia. 6 Patients with gout and renal failure usually receive a lower starting dose of allo purinol, 50 mg daily, and maintenance doses for these indivi duals frequently range from 100-300 mg per day. 6, 7 This low allopurinol dosage is neces sary owing to increased exposure to the allopurinol metabolite, oxypurinol, in patients with renal insufficiency or failure, which increases the risk of SCARs in these patients. 7 A starting dose of ≥1.5 mg per unit of estimated glomerular filtration rate has been associated with an increased risk of allopurinol-induced SCARs, 8 indicating that initial allopurinol dose is an important factor. Moreover, SCARs typically develop within weeks or a few months after initiating allopurinol treatment. Together, these observations support a lower starting dose of allopurinol, as endorsed by Hershfield and colleagues. 4 Hershfield et al. 4 also advised against the use of allopurinol for the treatment of asymptomatic hyperuricaemia (that is, in absence of gout), given the risk of SCARs and considering that treatment of asymptomatic hyperuricaemia with allopurinol has not been unequivocally shown to be beneficial. Other groups have made similar recommendations, although controversy exists in this area. Given the close association between HLAB*5801 positivity and allopurinolinduced SCARs, particularly in Asian populations-in which roughly 100% of allopurinol-induced SCAR cases involved HLAB*5801 + individuals-Hershfield et al. 4 recommend that allopurinol should not be prescribed to patients who have tested positive for this allele (Figure 1 ). Although only a small subset of HLAB*5801 + patients will develop SCARs, the authors nevertheless recommend that alternative medications should be considered for these patients to avoid this risk. 4 On the other hand, testing negative for this allele can eliminate the possibility of developing allopurinolinduced SCARs, primarily in Han-Chinese and Thai individuals. 4, 5 Patients who have tested nega tive for HLAB*5801 can, therefore, be prescribed allopurinol as usual. How ever, the authors recognize that test ing negative for HLAB*5801 does not totally eliminate the possibility of develop ing SCARs, especially in Europeans, a population in which only around 55% of the allopurinol-associated SCARs and AHS cases were associated with HLAB*5801 positivity. 4, 5 Further more, caution is needed as these observations are based on single studies within each population; additional studies are required to add more confidence and clarity to the gen etics of AHS and other SCARs, especially in European populations.
A diagnostic kit is currently commercially available for testing for the presence of the HLAB*5801 allele. Positive predictive values (PPV) and negative predictive values (NPV) of HLAB*5801 for AHS were ~1.5% and 100%, respectively, in Thai popu lations, 9 and are probably similar for Han-Chinese populations. Thus, as introduced above, HLAB*5801 provides excellent NPV, particularly in these populations (that is, if an individual is HLAB*5801 negative they have a low risk of developing AHS), but the PPV is much lower. The estimated HLAB*5801 allele carrier frequency is 6.1% in Asian populations, 4.3% in black people, 0.75% in white people, 1.2% in Hispanic indivi duals and 3.7% in Middle Eastern groups. 4 Therefore, the PPV of genotyping is likely to be slightly improved in European populations due to a lower overall of HLAB*5801 allele carrier frequency compared with Asian populations, 4 On the other hand, HLAB*5801 genotyping might not accurately rule out SCARs (especially in European popula tions) and will detect pseudodisease in some populations. Furthermore, the prevalence of allopurinol-induced SCARs is low, as most patients found to have the HLAB*5801 allele will not develop SCARs, limiting the utility of the test. 10 Thus, as a single test, HLAB*5801 genotyping is not foolproof in all populations; detection of new genetic factors is needed to further improve the predictive value of HLAB*5801 for SCARs and AHS before this biomarker can be used effectively in the clinic. The effectiveness of such a screening test is also likely to differ between populations, owing to differences in the baseline prevalence of the alleles used and the associated risk of allopurinol-induced SCARs. In this respect, HLAB*5801, which seems to be much less prevalent in white populations compared with Asian populations, 4 represents a key example of a potentially et hnospecific biomarker.
Prior to the discovery of an association between HLAB*5801 and AHS, use of diuretics and concomitant antibiotics were reported as risk factors for AHS; more data are needed to examine whether these associ ations hold true and are independent. Despite being challenging to study owing to the rarity of AHS, well-designed investigations can enable identification of novel risk factors and confirmation of suspected risk factors for allopurinol-associated SCARs. Such studies might aid the construction of a robust risk prediction measure incorporating HLAB*5801 status (and additional alleles identified as genetic risk factors) and clinical variables. Given the high mortality associated with AHS, the importance of its early diagnosis and treatment is obvious; however, practical strategies to prevent the condition are likely to prove far more effective and important overall than thera peutic approaches to treat this condition once it occurs.
The unfolding HLAB*5801 story has opened a new area of investigation regarding the application of pharmacogenomics in gout management and has improved by leaps and bounds our understanding of AHS and allopurinal-associated SCARs. As more studies replicate these innovative findings and identify new genetic and clinical risk factors, we might soon arrive at a point at which we are able to predict AHS and other SCARs with greater certainty. Such advances will enable us to save the lives of people at risk of this rare, sometime fatal, adverse effect of a commonly used medication, allopurinol, which is otherwise well tolerated and effective when used at the appropriate doses in patients with gout. 
